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Open access under CC BY-NC-ND license.Luminex, flow cytometry, quantitative RT-PCR, and
QuantiGene assays. The effects of PGD2 under physiologic
conditions were evaluated by using the supernatant from
activated mast cells.
Results: PGD2 binding to CRTH2 induced ILC2 migration and
production of type 2 cytokines and many other cytokines. ILC2
activation through CRTH2 also upregulated the expression of
IL-33 and IL-25 receptor subunits (ST2 and IL-17RA). The
effects of PGD2 on ILC2s could be mimicked by the supernatant
from activated human mast cells and inhibited by a CRTH2
antagonist.
Conclusions: PGD2 is an important and potent activator of
ILC2s through CRTH2 mediating strong proallergic
inflammatory responses. Through IgE-mediated mast cell
degranulation, these innate cells can also contribute to adaptive
type 2 immunity; thus CRTH2 bridges the innate and adaptive
pathways in human ILC2s. (J Allergy Clin Immunol
2014;133:1184-94.)
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Innate lymphoid cells (ILCs) are emerging as a novel family of
hematopoietic effectors that are heterogeneous in their location,
cytokine production, and effector functions.1-3 They lack specific
antigen receptors and lineage markers and serve critical roles in
innate immune responses to microorganisms, lymphoid tissue
formation, and tissue remodeling.2 ILCs can be categorized into
3 subsets (group 1 ILCs [ILC1s], group 2 ILCs [ILC2s], and
group 3 ILCs [ILC3s]) based on phenotypic and functional
characteristics.4
ILC2s are ILCs that produce type 2 cytokines (IL-4, IL-5, IL-9,
and IL-13) and are dependent on GATA3 and retinoic acid
receptor–related orphan receptor a for their development and
function.5-11 This group of cells is found in the blood, spleen,
intestine, liver, skin, fat-associated lymphoid clusters, and lymph
nodes of mice and have also previously been termed natural
helper cells, nuocytes, or innate helper 2 cells by different
groups,5,12-14 but the overall term ILC2 is now accepted.4 They
express IL-17RB (IL-25R) and ST2 (IL-33R) receptors and
respond to IL-25 (IL-17 family member) and IL-33 (IL-1 family
member). Such cells are thought to contribute to protection
against parasites and also promote allergic inflammation.15
Lung-resident ILC2s in mice have been shown to restore epithe-
lial integrity and lung function by producing amphiregulin, a
wound-healing regulator.16 Airway infection with H3N1 induced
airway hyperreactivity by stimulating alveolar macrophages
to produce IL-33 and therefore activating ILC2s.17 Similarly,
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models induces ILC2 infiltration into the lungs and airway
hyperreactivity.18,19 The human counterpart of mouse ILC2s
was recently discovered in human peripheral blood, lung tissue,
and fetal gut and skin and has been found in increased numbers
in inflamed nasal polyps and skin.16,20-22 ILC2s observed within
lesional atopic dermatitis skin is compatible with a role in patho-
genesis because increased production of IL-13 is well established
in atopic skin, leading to downregulation of antimicrobial
peptides and filaggrin.21,23,24 This human ILC population was
found also to express chemoattractant receptor-homologous
molecule expressed on TH2 cells (CRTH2).
20 A recent report
showed that prostaglandin D2 (PGD2) induced ILC2s to produce
IL-13 through activation of CRTH2 in a synergistic manner with
IL-25/IL-33.22 However, understanding of the role of CRTH2 in
these cells is still limited.
CRTH2 is a G protein–coupled receptor for PGD2, a major
mediator released from activated mast cells.25 Before the
discovery of ILC2s, CRTH2 was known to be abundant on
eosinophils, basophils, and TH2 cells. Emerging evidence
suggests that the activation of CRTH2 leads to proinflammatory
responses in leukocytes, including chemotaxis of eosinophils,
basophils, and TH2 cells
25-27; TH2 cytokine production,
28,29
which is enhanced by cysteinyl leukotrienes (cysLTs)30; and
proinflammatory protein expression.28,31 Our previous studies
also demonstrated that the signaling of CRTH2 suppresses TH2
cell apoptosis.32 Allergic responses mediated by IgE, mast cells,
TH2 cells, and eosinophils are dramatically reduced in mice in
which CRTH2 is genetically ablated or by small-molecule
CRTH2 antagonists.33-35 Antagonism of CRTH2 is currently
being tested as a useful approach to control allergic diseases.36
In this study we investigated the role of CRTH2 in human
ILC2s isolated ex vivo. We found that CRTH2 plays a critical role
in proinflammatory responses of ILC2s, including cell migration
and diverse cytokine production. Activation of CRTH2 also
upregulated the IL-33 and IL-25 receptors (ST2 and IL-17RA),
and the combination of PGD2, IL-33, and IL-25 enhanced some
ILC2 responses. These novel observations define CRTH2 as a
key trigger for ILC2 activation and thus places it at the center
of a tissue inflammation network.METHODS
ILC2 cell preparation and culture
Skin immune cells were isolated from the human skin biopsy specimens of
healthy donors. The tissue was cut and then digested in collagenase P at 378C
overnight. After washing with 10 mmol/L EDTA solution, cell suspensions
were obtained by passing through tissue strainers. Mononuclear cells were
isolated from the cell suspensions with Ficoll-Paque PLUS gradient. PBMCswere isolated from leukocyte cones (National Blood Service, Bristol, United
Kingdom) by using Lymphoprep gradient.
ILC2s were prepared from mononuclear cells and cultured by using a
modified method described previously.20 Briefly, CD31 T cells were prede-
pleted with CD3microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany);
otherwise, the mononuclear cells were labeled with an antibody mixture (see
Table E1 in this article’s Online Repository at www.jacionline.org). Lineage-
negative (CD3, CD4, CD8, CD14, CD19, CD56, CD11b, CD11c, FcεRI, and
CD123), CD45high, CD1271, and CRTH21 cells were sorted on aMoFlo XDP
cell sorter (Beckman Coulter, Fullerton, Calif) and cultured with 100 IU/mL
IL-2, 10% heat-inactivated human serum, 13 L-glutamine, 13 penicillin/
streptomycin, and gamma-irradiated PBMCs (from 3 healthy volunteers) in
RPMI 1640 (Sigma, St Louis, Mo). Half of the medium was replaced with
fresh medium every 2 to 3 days. The irradiated cells were degraded within 1
to 2 weeks of culture, and the purity of the ILC2s was confirmed by using
fluorescence-activated cell sorting before use. The cells were changed to fresh
medium without IL-2 before treatment.
Use of human tissue samples was conducted under the ethical approval of
the Oxford Clinical Research Committee.Human mast cell culture and activation
Human mast cells were cultured from CD341 progenitor cells and treated
with human IgE (Chemicon International, Temecula, Calif) and goat anti-
human IgE (1 mg/mL, Sigma) in the presence or absence of diclofenac
(10 mmol/L), as described previously.37 Supernatants of the cells were
collected and measured for PGD2 and IL-13 with ELISA or stored at
2808C until used as mast cell supernatants for the treatment of ILC2s.Chemotaxis assays
For measurement of cell migration, ILC2s were resuspended with RPMI
1640 media; 25 mL of cell suspension and 29-mL test samples prepared in
RPMI 1640 or mast cell supernatants were applied to the upper and lower
chambers, respectively, in a 5-mm pore sized 96-well ChemoTx plate
(Neuro Probe, Gaithersburg, Md). After incubation (378C for 60 minutes),
the migrated cells in the lower chambers were collected and mixed with a Cell
Titer-Glo Luminescent Cell Viability Assay kit (Promega, Madison, Wis)
and quantified by using a FLUOstar OPTIMA luminescence plate reader
(BMG LabTech, Cary, NC).Luminex assays
After ILC2 treatments for 4 hours, the concentrations of selected human
cytokines in the supernatants were measured by using a Procarta Human
Cytokine Immunoassay kit (Affymetrix, Santa Clara, Calif) with magnetic
beads, according to themanufacturer’s instruction. Results were obtainedwith
a Bio-Plex 200 System (Bio-Rad Laboratories, Hercules, Calif).QuantiGene Plex assays
After various treatments for 2.5 hours, the mRNA levels of selected genes
in ILC2s were measured by using a QuantiGene 2.0 Plex Assay kit
(Affymetrix) with magnetic beads, as per the manufacturer’s instruction.
Results were quantified with a Bio-Plex 200 System (Bio-Rad Laboratories).Quantitative RT-PCR
Quantitative RT-PCR was conducted, as described previously.30 Primers
and probes (Roche, Mannheim, Germany) used are listed in Table E2 in this
article’s Online Repository at www.jacionline.org.ELISA
Concentrations of cytokines in the supernatants of ILC2s ormast cells were
assayed with ELISA kits (R&D Systems, Minneapolis, Minn). PGD2 levels
in the supernatants of mast cells were assayed with a PGD2-MOX enzyme
FIG 1. ILC2 isolation. ILC2s isolated from human skin were lineage marker–negative (CD3, CD4, CD8, CD14,
CD19, CD56, CD11c, CD11 b, FcεRI, T-cell receptor gd, T-cell receptor ab, and CD123), CD45high, IL-7Ra1, and
CRTH21. Isotype controls are shown in Fig E1.
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measured in a FLUOstar OPTIMA luminescence plate reader (BMG
LabTech).
Flow cytometric analysis
ILC2s were fluorescently labeled with antibodies (see Table E1) and
acquired by using Summit software on a CyAn flow Cytometer (Beckman
Coulter).
Statistics
Data were analyzed by using 1-way ANOVA, followed by the Newman-
Keuls test. P values of less than .05 were considered statistically significant.RESULTS
CRTH2 mediates chemotaxis of human ILC2s
To understand the role of CRTH2 in human ILC2s, we
compared the effect of PGD2 with the effects of IL-33 and
IL-25 on ILC2 migration. Lineage-negative, CD45high,
CD1271, and CRTH21 ILC2s were isolated from human skin
biopsy specimens and peripheral blood of healthy adult donors
(Fig 1 and see Fig E1 in this article’s Online Repository at
www.jacionline.org) and tested with dose titrations of PGD2,
IL-33, and IL-25 in chemotaxis assays (Fig 2, A). Both PGD2
and IL-33 caused ILC2 migration in a dose-dependent manner,
peaking at approximately 100 nmol/L for PGD2 and 30 ng/mL
for IL-33. The chemoattractant effect of IL-25 on ILC2s was
very weak. The maximum response achieved with PGD2 was
4.75-fold higher than that achieved with IL-33. The ILC2s
cultured from skin and blood showed similar responses to
PGD2, IL-25, and IL-33.
To confirm the receptor mediating ILC2 migration induced by
PGD2 was CRTH2, we used the selective CRTH2 antagonist
TM30089. ILC2 migration triggered by PGD2 (30 nmol/L) was
completely inhibited by TM30089 (1 mmol/L; Fig 2, B).
The effects of combinations of these stimulators were
examined to further elucidate the contribution and interaction
of PGD2, IL-33, and IL-25 on ILC2migration (Fig 2,C). Concen-
trations of stimulators less than the peak in their dose curves(5 nmol/L for PGD2 and 10 ng/mL for IL-33 and IL-25) were
used for these combination tests to avoid saturation of the
response. No additive effect was detected when the stimulators
were combined. The cell migration in response to the combina-
tions of PGD2 and IL-33 or PGD2, IL-33, and IL-25 at these doses
appeared to bemainly mediated by CRTH2 because the responses
were largely inhibited by TM30089.
Activation of human ILC2s through CRTH2 induces
type 2 cytokine production
One of the most striking features of ILC2s is their ability to
produce type 2 cytokines.5 Cells were stimulated with increasing
concentrations of PGD2 for 2.5 hours for mRNA analysis or for 4
hours for protein analysis to investigate the role of CRTH2 in type
2 cytokine production in human ILC2s (Fig 3, A). The treatment
increased cytokine expression at the levels of both mRNA and
secreted protein in a dose-dependent manner (Fig 3, A). The
median effective concentration (EC50) of PGD2 for IL-4, IL-5,
and IL-13 production at the mRNA level was 88, 178, and 111
nmol/L, respectively, and that at the protein level was 195, 118,
and 82.6 nmol/L, respectively. Type 2 cytokine production
induced by 100 nmol/L PGD2 was completely blocked with 1
mmol/L TM30089 (Fig 3, B).
It has been reported that IL-33 and IL-25 promote type 2
cytokine production from ILC2s.5,38,39 ILC2s were treated with
PGD2, IL-33, or IL-25 alone (at concentrations close to their
relative EC50) or in combination for 4 hours to define the effect
of the combination of PGD2, IL-33, and IL-25 on type 2 cytokine
production (Fig 3, B). Both IL-33 and IL-25 evoked type 2
cytokine production from ILC2s. In contrast, IL-33 had no effect
on Lin2CD1271CRTH22 cells (see Fig E2 in this article’s Online
Repository at www.jacionline.org). However, the efficacy of both
IL-33 and IL-25 at this time point was weaker than that of PGD2
in ILC2s from both skin and blood. Interestingly, the combination
of IL-33 and IL-25 at these doses did not enhance stimulation
compared with either IL-33 or IL-25 alone; however, the
combination of these cytokines, particularly IL-25 with PGD2,
enhanced cytokine production with an apparent synergistic effect.
FIG 2. Migration of ILC2s (A and B, skin; C, blood) to PGD2 is mediated by CRTH2. Fig 2, A, Migration after
stimulation with IL-25, IL-33, or PGD2. Fig 2, B, Migration after exposure to PGD2 in the absence or presence
of TM30089. Fig 2, C, Migration in response to PGD2, IL-33, or IL-25 alone or in combination with or without
TM30089. *P < .05 (n 5 3).
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effectively blocked by TM30089.
Activation of human ILC2s through CRTH2
regulates other cytokine production
The effect of CRTH2 on other cytokine production was
investigated to further understand the proinflammatory role of
CRTH2 in ILC2s (Fig 4). Cells were incubated with increasing
concentrations of PGD2 for 4 hours, and protein levels of IL-3,
IL-8, IL-9, IL-17A, IL-17F, IL-21, GM-CSF, macrophage
colony-stimulating factor (CSF-1), and IFN-g were measured.
PGD2 induced the production of IL-3, IL-8, IL-9, IL-21,
GM-CSF, and CSF-1 in a dose-dependent manner (Fig 4, A).
The EC50 of PGD2 for IL-3, IL-8, IL-9, IL-21, GM-CSF, and
CSF-1 was 79.8, 65.7, 47.4, 43, 132.5, and 29.2 nmol/L, respec-
tively. No IL-17A, IL-17F, or IFN-g was detected (data not
shown). As for type 2 cytokines, the production of IL-3, IL-8,
IL-9, IL-21, GM-CSF, and CSF-1 induced by PGD2, both at
mRNA and protein levels, was enhanced by combination with
IL-33 and IL-25. This enhancement was particularly significant
for IL-8, IL-9, and GM-CSF production (Fig 4, B). In contrast,
the mRNA level of IFN-g was downregulated by PGD2 at
nanomolar concentrations (Fig 4, C). The regulatory effects of
PGD2 on these cytokines, whether activating or inhibitory, were
reversed by TM30089 (1 mmol/L; Fig 4, B and C).PGD2 upregulates IL-33 receptors but
downregulates CRTH2 expression in human ILC2s
To explore the potential interaction between IL-33/IL-25–
mediated and PGD2-mediated immune responses, we examinedthe effect of these activators on the expression of their receptors
in ILC2s (Fig 5). After 2.5 hours of stimulation with PGD2,
mRNA levels for ST2 was increased significantly, mRNA levels
for the IL-17RA subunit of the IL-25 receptor were also
upregulated slightly, and mRNA levels for CRTH2 were reduced
markedly (Fig 5, A, and see Fig E3 in this article’s Online
Repository at www.jacionline.org). The effect on the expression
of the IL-17RB subunit of the IL-25 receptor was minor.
Treatment with IL-33 or IL-25 alone had no significant effect
on the expression of these receptors at this time point; however,
the combination of PGD2, IL-33, and IL-25 enhanced the
upregulation of ST2 mRNA (Fig 5, A). The CRTH2-dependent
regulation of these receptors was inhibited by TM30089.
To verify the regulation of these receptors at the protein level,
the expression of ST2 and CRTH2 on the cell surface of ILC2s
was analyzed by using fluorescence-activated cell sorting after
treatment with PGD2 (150 nmol/L) in the presence or absence of
TM30089 (1 mmol/L; Fig 5, B and C). ST2-positive cells
increased from 14.3% to 25.2% after 4 hours of treatment with
PGD2, and this was inhibited by TM30089 (Fig 5, B). Decreased
expression of CRTH2was detected after 6 hours of treatment with
PGD2, and the blockade of CRTH2 activity by using TM30089
inhibited this downregulation (Fig 5, C).Human mast cell–derived PGD2 triggers ILC2s
through CRTH2
Mast cells are the major source of PGD2 during allergic
responses.40,41 The effect of endogenously synthesized PGD2
from activated human mast cells on ILC2s was examined to
confirm the activation of CRTH2 in ILC2s under physiologic
FIG 3. CRTH2 mediates type 2 cytokine production in ILC2s (skin) in response to PGD2. A, mRNA levels of
cytokines in cells (mRNA) and cytokine concentrations in supernatants (protein) after incubation with
various concentration of PGD2. B, Concentrations of cytokines released after treatments are as indicated.
*P < .05 between control and other treatments and **P < .05 between PGD2 and indicated treatments
(n 5 3).
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6 cell/mL)
were detectable in supernatants from resting mast cells. After
activation with IgE followed by anti-IgE antibody cross-linking,
mast cell cultures produced high PGD2 levels (>11 ng/2 3 10
6
cell/mL; Fig 6, A). Cotreatment of IgE/anti-IgE–activated mast
cells with diclofenac (10 mmol/L), an inhibitor of COX-2, during
the period of anti-IgE stimulation abolished PGD2 production
(<0.2 ng/2 3 106 cell/mL; Fig 6, A). Only very low levels of
IL-13 (<200 pg/23 106 cell/mL) could be detected in any of these
mast cell supernatants.
The supernatants of these mast cell treatments were used to test
the effects of endogenous PGD2 in human ILC2s. Notably, the
capacities of the supernatants to activate ILC2s were dependent
on the PGD2 levels in the supernatants (Fig 6 and see Fig E4 in
this article’s Online Repository at www.jacionline.org). The
supernatant containing high levels of PGD2 (supernatant 2)
but not the supernatant derived from the resting mast cells
(supernatant 1) induced strong cell migration (Fig 6, B) and
type 2 cytokine production (Fig 6, C). Treatment of ILC2s with
supernatant 2 also caused the production of other proinflamma-
tory cytokines (IL-3, IL-8, IL-9, IL-21, GM-CSF, and CSF-1;
see Fig E4). Blockade of PGD2 synthesis with diclofenac
(supernatant 3) removed most of the capacity to stimulate
ILC2s, particularly for type 2 cytokines (Fig 6,B andC), althoughthe effect of diclofenac on production of IL-3, IL-9, and CSF-1
was not significant (see Fig E4). These ILC2 cell responses to
supernatant 2 were blocked by TM30089 (Fig 6, B and C, and
see Fig E4). BWA868C, an antagonist for D prostanoid receptor
(another PGD2 receptor), and montelukast, an antagonist for
cysteinyl leukotriene receptor 1 (CysLT1), were used to further
confirm the receptor involved (see Fig E5 in this article’s Online
Repository at www.jacionline.org). Montelukast, but not
BWA868C, inhibited production of IL-3, IL-13, and GM-CSF
significantly in ILC2s in response to supernatant 2, and
combination of TM30089 and montelukast blocked the response
completely.
Similar to the results from experiments with exogenous
PGD2, the supernatant from activated mast cells upregulated
the mRNA of ST2 mRNA significantly and IL-17RA weakly
and downregulated CRTH2 mRNA in ILC2s (Fig 6, D). These
effects were also inhibited by TM30089.DISCUSSION
Activation of group 2 ILCs leads to the production of classical
type 2 cytokines, thus promoting type 2 immunity. Increased
numbers of ILC2s have been observed in inflamed tissues, such as
allergic lung tissue in mice18,19 and nasal polyps20 and skin21 in
FIG 4. Activation of CRTH2 evokes proinflammatory cytokine production in ILC2s (skin). A, Cytokine
concentrations after stimulation with PGD2. B, mRNA levels of cytokines (mRNA) and concentrations of
cytokines (protein) after treatments, as indicated. C,mRNA level of IFN-g after treatments. *P < .05 between
control and other treatments and **P < .05 between PGD2 and indicated treatments (n 5 3).
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expressed in human ILC2s and that the activation of this receptor
leads to IL-13 release from the cells.20,22 Herewe have shown that
PGD2 elicits many strong proinflammatory responses in ex vivo
ILC2s isolated from human skin and blood. In contrast to Kimet al,21 who did not identify CD1611CRTH21 ILC2s in healthy
human skin, we managed to isolate these cells from the normal
human skin, although they were in low proportion. PGD2 induced
migration of these cells and promoted production of type 2 cyto-
kines (IL-4, IL-5, and IL-13) and many other proinflammatory
FIG 5. Activation of CRTH2modulates receptor expression in ILC2s (A, blood; B and C, skin). Fig 5,A, mRNA
levels of receptor genes after treatments (n 5 3). The expression of ST2 (Fig 5, B) and CRTH2 (Fig 5, C) in
ILC2s after incubation with medium or PGD2 with or without TM30089 for 4 (Fig 5, B) or 6 (Fig 5, C) hours,
as determined by using fluorescence-activated cell sorting, is shown.
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stimulatory effect of PGD2 was mediated by CRTH2 because it
was inhibited completely by a specific CRTH2 antagonist
TM30089.32 These proinflammatory roles of CRTH2 in ILC2s
could be confirmed under pathophysiologic conditions by using
endogenously synthesized PGD2 from humanmast cells activated
through IgE binding. Therefore our study reveals a potent
mechanism for ILC2 activation in type 2 immunity.
A number of studies have recently identified the epithelium-
derived cytokines IL-25 and IL-33 as critical activators of
ILC2-mediated innate immunity against parasite infection and
responses to allergen challenge.15,42,43 Lack of these cytokines
delays the onset of type 2 responses mediated by ILC2s in mouse
models.5,44,45 In our studies of human ILC2s, administration of
IL-33 initiated cell migration and type 2 cytokine production.
IL-25 also induced cytokine production, although the effect on
chemotaxis was marginal. However, the efficacy of IL-25 and
IL-33 was weaker than that of PGD2 during the tested time points,
suggesting that PGD2 could be another important activator of
ILC2s. As reported by Barnig et al,22 combination treatment
with PGD2, IL-33, and IL-25 enhanced cytokine production by
ILC2s, although no synergistic effect on chemotaxis was
seen. Interestingly, activation of CRTH2 strongly upregulated
expression of the IL-33 receptor ST2 and moderately upregulated
the IL-25 receptor subunit IL-17A. Therefore IL-25, IL-33, and
PGD2 could act in concert in ILC2-mediated immune responses.ILC2s are enriched at sites of inflammation after parasitic
infection or allergic challenge,14,18-20 but the mechanism
involved in their recruitment remains obscure. IL-33 caused
ILC2 migration in a dose-dependent manner, although the
efficacy of IL-33 was weaker than that of PGD2. The migration
of ILC2s toward PGD2 was completely inhibited by a CRTH2
antagonist, implying that CRTH2 is an important chemoattractant
receptor in human ILC2s. Neither IL-25 nor IL-33 potentiated the
migration of ILC2s in response to PGD2, suggesting that if the 3
activators coexisted in inflamed tissue, PGD2 could serve as a
dominant contributor to the recruitment cascade of ILC2s.
It is well established that activation of ILC2s is characterized
by the production of high levels of type 2 cytokines that in turn
affect antibody class-switching, recruitment of inflammatory
effector cells (eg, eosinophils, basophils, and mast cells), and
goblet cell hyperplasia leading to mucus production, all of which
contribute to the immune responses to parasite infection, allergen
challenge, and tissue damage.1,6,7 In this study we demonstrated
that ILC2s are capable of producing many other proinflammatory
cytokines after activation, including IL-3, IL-8, IL-21, GM-CSF,
and CSF-1. These cytokines could also play important roles in
orchestrating ILC2-mediated immune responses. IL-3 can be
critical for the growth and differentiation of CD341 progenitor
cells into basophils and mast cells and monocytes into dendritic
cells.46,47 IL-8 is a potent chemokine for neutrophils,48,49 a cell
type that is associated with severe asthma.50,51 IL-21 can induce
FIG 6. Effect of mast cell supernatants on activation of ILC2s (skin) is mediated by CRTH2. A, Levels of PGD2
and IL-13 in supernatants of mast cells treated with medium (white bars) or IgE/anti-IgE antibody with
(black bars) or without (gray bars) diclofenac. Supernatants were assigned as supernatants 1 to 3. B, ILC2
migration after exposure to supernatants with or without TM30089. C and D, mRNA and protein levels of
cytokines (Fig 6, C) and mRNA levels of receptors (Fig 6, D) in ILCs after incubation with supernatants
with or without TM30089 for 3 hours. *P < .05 (n 5 2).
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neutrophil and monocyte populations52 and is also involved in
the pathogenesis of allergic disorders and autoimmune diseases
(including inflammatory bowel diseases, rheumatoid arthritis,
psoriasis, and systemic lupus erythematosus) by controlling the
growth, survival, differentiation, and function of T and B
cells.53-57 GM-CSF and CSF-1 also contribute to allergic and
autoimmune diseases.58,59 GM-CSF is critical for eosinophil
and neutrophil survival and their activities.60,61 Overexpression
of GM-CSF in mice enhances and anti–GM-CSF antibodies
inhibit allergic sensitization and airway inflammation.62-64 IL-3
and GM-CSF are coordinately induced with IL-4, IL-5, IL-9,
and IL-13, and their genes also cluster on the same chromosome
locus, 5q31-33, a major susceptibility locus for asthma and
atopy.65 In contrast, the activation of CRTH2 downregulated
gene transcription levels of IFN-g in ILC2s, suggesting that
CRTH2 signaling could potentially favor viral infection. In fact,an unexpected efficacy in reduction of viral infection by one
CRTH2 drug has been observed in clinical trials.66 Therefore
through activation of CRTH2, ILC2s might be involved in other
as yet unrecognized immune responses.
PGD2 is the major arachidonic acid metabolite released from
mast cells during allergic responses.40,41,67 High concentrations
of PGD2 are detected in the airways of asthmatic patients
challenged with allergen,68 and increased activation of the
PGD2 pathway has been found in patients with severe asthma.
69
To determine whether CRTH2-mediated activation of ILC2s
was functioned under physiologic conditions, we examined the
effect on ILC2s of endogenously synthesized PGD2 from human
mast cells. The ILC2 cell responses to mast cell supernatants were
similar to those seen to exogenously synthesized PGD2. The only
difference was that some responses to the mast cell supernatants
could not be completely blocked by the CRTH2 antagonist or
by inhibition of PGD2 synthesis. This could be caused by the
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cells in the supernatant, which drive production of specific
cytokines. Our data with montelukast suggested that cysLTs are
also important ILC2 stimulators. Mast cells are found mainly in
epithelial barriers, such as skin and mucosal tissues, and increase
in number after exposure to allergens.70 In mouse skin ILC2s
migrated specifically toward and interacted with skin-resident
mast cells,14 and ILCs were also found in proximity to tissue
mast cells in human lungs.22 Therefore ILC2s can also contribute
to mast cell–mediated type 2 immunity.11 Although multiple
stored or de novo–synthesized inflammatory mediators are
released from activated mast cells,37 it is striking that ILC2
migration and type 2 cytokine production in response to mast
cell supernatant can be inhibited mostly by CRTH2 antagonism
(Fig 6), making it likely that PGD2/CRTH2 serves as a dominant
link between activated mast cells and activation of ILC2s. Mast
cells orchestrate adaptive type 2 immunity to helminths or
allergen through IgE/FcεRI-dependent activation.71 However,
mast cells can also be nonspecifically activated in IgE/
FcεRI-independent ways by substances such as peptides, basic
compounds, anaphylatoxins, dextrans, and cytokines.71-73 Many
studies have revealed the critical role of PGD2/CRTH2 in adaptive
type 2 immunity, particularly in mast cell–mediated activation of
TH2 cells and eosinophils.
25,26,28,29,31 Here we further extend
their role to the activation of ILC2s. Beyond this, PGD2
production can also be induced by innate responses, such as
macrophages activated by double-stranded RNA through
Toll-like receptor 3.74 Therefore ILC2 activation induced by
PGD2 could be mediated by either innate or adaptive immune
pathways.
Our previous study revealed that the type 2 cytokine production
in human TH2 cells mediated by CRTH2 was markedly enhanced
by another group ofmast cell mediators, cysLTs.30 A recent report
has described that ILC2s in lungs of mice express CysLT1, which
regulates type 2 cytokine production.75 We have also confirmed
the expression of CysLT1 in human ILC2s (data not shown).
The combination of TM30089 and montelukast enhanced their
inhibitory effect on cytokine production in ILC2s in response to
mast cell supernatant. This suggests that CRTH2 and leukotriene
receptors could also act synergistically in mast cell–mediated
human ILC2 activation. Furthermore, by producing cytokines
(IL-3, IL-4, and IL-13), activation of ILC2s could in turn enhance
mast cell activation. Given the association with tissue mast cells
and allergic skin disease, it might be that the inhibition of
PGD2-mediated recruitment and activation of ILC2s through
CRTH2 might provide a therapeutic opportunity for atopic
dermatitis.
In conclusion, the current study highlights the important
proinflammatory role of CRTH2 and its ligand, PGD2, in
human ILC2s, and potential roles of ILC2s in IgE/mast cell/
CRTH2–mediated adaptive immune cascades. In addition to
IL-25 and IL-33, PGD2 is clearly another important and potent
driving force in ILC2 activation. It can directly stimulate
ILC2s through CRTH2 and can also potentiate IL-25/IL-33–
mediated innate responses. Through IgE-mediated mast cell
degranulation, ILC2s can contribute to both innate and adaptive
type 2 immunity, and through upregulation of IL-33/IL25
receptors and synergistic interaction with these receptors,
CRTH2 plays a pivotal role in bridging innate and adaptive
pathways in ILC2s.We thank Fiona Powrie for critical reading of this manuscript.
Key messages
d PGD2 activates human ILC2s through CRTH2 and in-
duces strong proinflammatory responses, which can serve
as a potential therapeutic opportunity for IgE/mast cell/
ILC2–mediated allergic inflammation.
d Through sensing IgE-mediated mast cell degranulation,
ILC2s can contribute to both innate and adaptive type 2
immunity.
d Through upregulation of IL-33/IL-25 receptors and syn-
ergistic interaction to these receptors, CRTH2 plays a
pivotal role in bridging innate and adaptive pathways in
human ILC2s.
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FIG E1. Isotype controls for ILC2 isolation (Fig 1).
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FIG E2. Comparison of Lin2CD1271CRTH22 and Lin2CD1271CRTH21 cells from human skin. A, Expression
of ST2 (blue line) on CRTH22 cells was much lower than expression on CRTH21 cells. The red line shows
unstained cells. B, Lin2CD1271CRTH21 (white columns) but not Lin2CD1271CRTH2- cells (black columns)
responded to IL-33 stimulation by IL-13 production (n 5 2).
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FIG E3. Expression of ST2, IL-17RA, and CRTH2 in ILC2s (skin) is regulated by PGD2 in a dose-dependent
manner. The mRNA level of ST2, CRTH2, IL-17RA, and IL-17RB in the cell pellets of ILC2s after stimulation
with various concentrations of PGD2 is shown. The mRNA levels in the cells treated with 1 nmol/L PGD2
were treated as 1-fold (n 5 2).
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FIG E4. CRTH2 mediates proinflammatory cytokine production in ILC2s (skin) in response to supernatants
from activated mast cells. Concentrations of IL-3, IL-8, IL-9, IL-21, GM-CSF, and CSF-1 in supernatants
after ILC2 incubation with 1:1.5 diluted supernatants of mast cells treated with medium (white bars) or IgE/
anti-IgE antibody with (black bars) or without (gray bars) diclofenac in the presence or absence of TM30089
for 3 hours. *P < .05 (n 5 2).
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FIG E5. Cytokine production by ILC2s (skin) in response to supernatants from activated mast cells is
inhibited by CysLT1 antagonist partially but not by D prostanoid receptor antagonist. The effects of
TM30089, BWA868C, montelukast, and their combination on the production of IL-13 (protein), IL-3, and
GM-CSF (mRNA) in ILC2s treated with the supernatant from IgE/anti-IgE-activated mast cells (gray bars)
were examined with ELISA or quantitative RT-PCR (n 5 1).
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TABLE E1. Antibody list used for ILC2 purification
Antigen Clone Supplier
CD3 SK7 BD Biosciences, San Jose, Calif
CD19 SJ25C1 BD Biosciences
CD123 FAB301C R&D Systems, Minneapolis, Minn
CD11b DCIS1/18 Abcam, Cambridge, United Kingdom
CD11c BU15 Abcam
CD8 RPA-T8 BioLegend, San Diego, Calif
FcεRI AER-37 (CRA-1) BioLegend
CD14 M4P9 BD Biosciences
CD4 MEM-241 Abcam
CD45 H130 BioLegend
CD56 B159 BioLegend
CRTH2 BM16 Miltenyi Biotec, Bergisch Gladbach, Germany
IL-7Ra A019D5 BioLegend
ST2 Ab72778 Abcam
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TABLE E2. Primers and probes used for quantitative RT-PCR
Gene Primer Probe no.
IL4 59-CACCGAGTTGACCGTAACAG-39
59-GCCCTGCAGAAGGTTTCC-39
16
IL5 59-GGTTTGTTGCAGCCAAAGAT-39
59-TCTTGGCCCTCATTCTCACT-39
25
IL13 59-AGCCCTCAGGGAGCTCAT-39
59-CTCCATACCATGCTGCCATT-39
17
IL17A 59-TGGGAAGACCTCATTGGTGT-39
59-GGATTTCGTGGGATTGTGAT-39
8
IL17F 59-GGCATCATCAATGAAAACCA-39
59-TGGGGTCCCAAGTGACAG-39
10
IFNG 59-GGCATTTTGAAGAATTGGAAAG-39
59-TTTGGATGCTCTGGTCATCTT-39
21
CRTH2 59-CCTGTGCTCCCTCTGTGC-39
59-TCTGGAGACGGCTCATCTG-39
43
IL1RL1 59-TTGTCCTACCATTGACCTCTACAA-39
59-GATCCTTGAAGAGCCTGACAA-39
56
IL17RA 59-CATCCTGCTCATCGTCTGC-39
59-GCCATCGGTGTATTTGGTGT-39
85
IL17RB 59-GCCCTTCCATGTCTGTGAAT-39
59-CCGGCCTTGACACACTTT-39
64
GAPDH 59-AGCCACATCGCTCAGACAC-39
59-GCCCAATACGACCAAATCC-39
60
GAPDH, Glyceraldehyde-3-phosphate dehydrogenase.
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